Mental Health

The Jefferies London Healthcare Conference will consist of both in-person one-on-one meetings from November 16-17 in London, England and virtual meetings from November 18-19. Members of Small Pharma’s management team will be hosting meetings throughout the conference.  To schedule a meeting, please contact your assigned Jefferies representative at

Press Releases

LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at the LSX Inv€$tival ShowcaseTM conference and the Jefferies London Healthcare Conference during the month of November.


Lucid News has published an article covering the landscape of companies working to create DMT Therapies. Once considered fringe medicine and the domain of maverick clinical researchers, innovators in the psychedelics field are now poised to make a significant contribution to the mental health landscape worldwide.  The article covers some of the cutting-edge research being […]


A clinical trial involving a psychedelic drug and psychotherapy aims to help patients with hard-to-treat depression and other mental health disorders A UK neuropharmaceutical company is planning the world’s first clinical trial to treat depression by combining psychotherapy and the mind-expanding psychedelic medicine dimethyltryptamine (DMT).  DMT is a naturally occurring chemical found in tiny amounts […]

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: